AbbVie Inc. ABBV

264.34 (0.78) (0.29%) as of 25 Sep
Market cap
$467.4B
P/E
74.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

AbbVie Inc. (ABBV) Price to free cash flow

As of 25 September 2026, AbbVie Inc. (ABBV) trades at a price to free cash flow of 25.7×. Over the past ten years it has ranged from 7.3× (August 2019) to 36.7× (January 2015); the current reading is higher than 95% of that period. That is above the Drug Manufacturers General industry median of 17.7× and above the Healthcare sector median of 19.5×.

Price to free cash flow, daily

Annual

Period Price to free cash flow Change
FY2025 22.7× 28.70%
FY2024 17.6× 37.64%
FY2023 12.8× 7.99%
FY2022 11.9× 8.82%
FY2021 10.9× 2.44%
FY2020 10.6× 3.62%
FY2019 10.3× (7.58%)
FY2018 11.1× (33.30%)
FY2017 16.7× 7.96%
FY2016 15.4× 12.22%

Quarterly

Period Price to free cash flow Change
Jun 2026 24.4× 26.88%
Mar 2026 19.3× (15.08%)
Dec 2025 22.7× 9.03%
Sep 2025 20.8× 15.65%
42 more quarters

Against its own ten years

Low 7.3× High 36.7×
Ten-year median 13.3×
Current reading's percentile 95

Price to free cash flow against peers

Company Price to free cash flow
GILD Gilead Sciences, Inc. compare 14.5×
PFE Pfizer Inc. compare 16.0×
NVS Novartis AG compare 18.3×
MRK Merck & Co., Inc. compare 22.9×
AMGN Amgen Inc. compare 23.0×
ABBV AbbVie Inc. 25.7×
JNJ Johnson & Johnson compare 28.7×
AZN AstraZeneca PLC compare 41.2×
LLY Eli Lilly and Company compare 51.8×
Drug Manufacturers General industry median 17.7×
Healthcare sector median 19.5×
Market median 14.0×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on ABBV